Prevalence and risk factors of atrophic gastritis and intestinal metaplasia: a nationwide multicenter prospective study in Korea

Young-Eun Joo, Hyun-Kyung Park, Dae-Seong Myung, Gwang-Ho Baik, Jeong-Eun Shin, Geom-Seog Seo, Gwang Ha Kim, Heung Up Kim, Hyun Young Kim, Sung-Il Cho, Nayoung Kim, Young-Eun Joo, Hyun-Kyung Park, Dae-Seong Myung, Gwang-Ho Baik, Jeong-Eun Shin, Geom-Seog Seo, Gwang Ha Kim, Heung Up Kim, Hyun Young Kim, Sung-Il Cho, Nayoung Kim

Abstract

Background/aims: Atrophic gastritis (AG) and intestinal metaplasia (IM) are premalignant gastric lesions. The aims of this study were to evaluate the prevalence of endoscopic AG and IM and to document the risk factors for these lesions.

Methods: In total, 4,023 subjects were enrolled at eight hospitals in Korea. AG and IM were diagnosed by endoscopy. Helicobacter pylori immunoglobulin G antibodies were measured.

Results: The prevalences of endoscopic AG and IM were 40.7% and 12.5%. In a multivariate analysis, the risk factors for AG were age groups of 40 to 59 years and >60 years, male sex, positive H. pylori serology, IM, and education below the college level (odds ratio [OR], 2.55, 5.00, 1.38, 1.41, 4.29, and 1.35, respectively). The risk factors for IM were age groups of 40 to 59 years and >60 years, male sex, positive H. pylori serology, AG, having relatives with gastric cancer, education below the college level and consumption of dairy products (OR, 3.16, 3.25, 1.88, 2.17, 3.68, 1.48, 1.47, and 1.40, respectively).

Conclusions: A nationwide survey regarding the prevalence of endoscopic AG and IM and their risk factors in Korea supports the hypothesis that endoscopic diagnosis of these premalignant lesions could be helpful to describe a group at high risk for gastric cancer.

Keywords: Atrophic gastritis; Endoscopy; Intestinal metaplasia; Prevalence; Risk factors.

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Prevalence of atrophic gastritis (A) and intestinal metaplasia (B) in each age group. The prevalence of atrophic gastritis and intestinal metaplasia increased significantly with age.

References

    1. Katanoda K, Yako-Suketomo H. Comparison of time trends in stomach cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, vols IV-IX. Jpn J Clin Oncol. 2009;39:71–72.
    1. Yuasa N, Nimura Y. Survival after surgical treatment of early gastric cancer, surgical techniques, and long-term survival. Langenbecks Arch Surg. 2005;390:286–293.
    1. Park JM, Ryu WS, Kim JH, et al. Prognostic factors for advanced gastric cancer: stage-stratified analysis of patients who underwent curative resection. Cancer Res Treat. 2006;38:13–18.
    1. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer. 2000;88:921–932.
    1. de Vries AC, Haringsma J, Kuipers EJ. The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection. Helicobacter. 2007;12:1–15.
    1. Kim N, Park RY, Cho SI, et al. Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow-up. J Clin Gastroenterol. 2008;42:448–454.
    1. Sipponen P, Kekki M, Haapakoski J, Ihamäki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer. 1985;35:173–177.
    1. Kim N, Park YS, Cho SI, et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease. Helicobacter. 2008;13:245–255.
    1. You WC, Zhang L, Gail MH, et al. Precancerous lesions in two counties of China with contrasting gastric cancer risk. Int J Epidemiol. 1998;27:945–948.
    1. Tatsuta M, Iishi H, Nakaizumi A, et al. Fundal atrophic gastritis as a risk factor for gastric cancer. Int J Cancer. 1993;53:70–74.
    1. Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, et al. A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol. 2004;57:177–182.
    1. Kuipers EJ, Uyterlinde AM, Peña AS, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet. 1995;345:1525–1528.
    1. Petersson F, Borch K, Franzén LE. Prevalence of subtypes of intestinal metaplasia in the general population and in patients with autoimmune chronic atrophic gastritis. Scand J Gastroenterol. 2002;37:262–266.
    1. Borch K, Jönsson KA, Petersson F, Redéen S, Mårdh S, Franzén LE. Prevalence of gastroduodenitis and Helicobacter pylori infection in a general population sample: relations to symptomatology and life-style. Dig Dis Sci. 2000;45:1322–1329.
    1. Asaka M, Sugiyama T, Nobuta A, Kato M, Takeda H, Graham DY. Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study. Helicobacter. 2001;6:294–299.
    1. Eshmuratov A, Nah JC, Kim N, et al. The correlation of endoscopic and histological diagnosis of gastric atrophy. Dig Dis Sci. 2010;55:1364–1375.
    1. Gold BD. New approaches to Helicobacter pylori infection in children. Curr Gastroenterol Rep. 2001;3:235–247.
    1. Muñoz N, Kato I, Peraza S, et al. Prevalence of precancerous lesions of the stomach in Venezuela. Cancer Epidemiol Biomarkers Prev. 1996;5:41–46.
    1. Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res. 1990;50:4737–4740.
    1. Guarner J, Herrera-Goepfert R, Mohar A, et al. Gastric atrophy and extent of intestinal metaplasia in a cohort of Helicobacter pylori-infected patients. Hum Pathol. 2001;32:31–35.
    1. Kuipers EJ. Review article: Relationship between Helicobacter pylori, atrophic gastritis and gastric cancer. Aliment Pharmacol Ther. 1998;12(Suppl 1):25–36.
    1. Cheng H, Hu F, Zhang L, et al. Prevalence of Helicobacter pylori infection and identification of risk factors in rural and urban Beijing, China. Helicobacter. 2009;14:128–133.
    1. Ito LS, Oba-Shinjo SM, Marie SK, et al. Lifestyle factors associated with atrophic gastritis among Helicobacter pylori-seropositive Japanese-Brazilians in Sao Paulo. Int J Clin Oncol. 2003;8:362–368.
    1. Dhillon PK, Farrow DC, Vaughan TL, et al. Family history of cancer and risk of esophageal and gastric cancers in the United States. Int J Cancer. 2001;93:148–152.
    1. Shin CM, Kim N, Yang HJ, et al. Stomach cancer risk in gastric cancer relatives: interaction between Helicobacter pylori infection and family history of gastric cancer for the risk of stomach cancer. J Clin Gastroenterol. 2010;44:e34–e39.
    1. Chang YW, Han YS, Lee DK, et al. Role of Helicobacter pylori infection among offspring or siblings of gastric cancer patients. Int J Cancer. 2002;101:469–474.
    1. El-Omar EM, Oien K, Murray LS, et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology. 2000;118:22–30.
    1. Leung WK, Ng EK, Chan WY, et al. Risk factors associated with the development of intestinal metaplasia in first-degree relatives of gastric cancer patients. Cancer Epidemiol Biomarkers Prev. 2005;14:2982–2986.
    1. Kim N, Kim JJ, Choe YH, et al. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol. 2009;54:269–278.
    1. Jarosz M, Rychlik E, Siuba M, et al. Dietary and socio-economic factors in relation to Helicobacter pylori re-infection. World J Gastroenterol. 2009;15:1119–1125.
    1. Sachdeva A, Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol. 2009;21:45–53.
    1. Kim MN, Kim N, Lee SH, et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter. 2008;13:261–268.
    1. Offerhaus GJ, Price AB, Haot J, et al. Observer agreement on the grading of gastric atrophy. Histopathology. 1999;34:320–325.
    1. el-Zimaity HM, Graham DY, al-Assi MT, et al. Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol. 1996;27:35–41.
    1. Satoh K, Kimura K, Taniguchi Y, et al. Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am J Gastroenterol. 1998;93:569–573.
    1. Correa P. Chronic gastritis: a clinico-pathological classification. Am J Gastroenterol. 1988;83:504–509.
    1. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1:87–97.
    1. Liu Y, Uemura N, Xiao SD, Tytgat GN, Kate FJ. Agreement between endoscopic and histological gastric atrophy scores. J Gastroenterol. 2005;40:123–127.
    1. Redéen S, Petersson F, Jönsson KA, Borch K. Relationship of gastroscopic features to histological findings in gastritis and Helicobacter pylori infection in a general population sample. Endoscopy. 2003;35:946–950.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit